Lilly agrees to acquire Adverum Biotechnologies

Eli Lilly has finished buying Adverum Biotechnologies, a clinical-stage gene therapy company working on a one-time injection for a common cause of vision loss. The two companies announced a merger agreement on October 24, 2025, and said on December 9, 2025, that the tender offer had expired and the deal would close that day ^[1][2].

The purchase price was structured in two parts. Lilly's subsidiary, Flying Tigers Acquisition Corporation, offered $3.56 per share in cash, plus one non-tradable contingent value right per share worth up to an additional $8.91 in later cash payments — a total of up to $12.47 per share if everything pays out ^[1][2]. The total dollar value of the deal has not been disclosed.

Those extra payments are tied to results, not to the closing. Up to $1.78 per contingent value right is due if Ixo-vec, Adverum's lead candidate, wins U.S. approval before the seventh anniversary of the closing. Another $7.13 per right is due the first time annual worldwide net sales of Ixo-vec pass $1.0 billion, if that happens before the tenth anniversary ^[1]. Both companies caution that there is no guarantee any of that contingent money will ever be paid ^[2].

What Lilly bought

Ixo-vec, or ixoberogene soroparvovec, is an experimental gene therapy for wet age-related macular degeneration, a chronic retinal disease that affects millions of people worldwide ^[1]. Today, wet AMD is usually managed with repeated injections into the eye of anti-VEGF drugs. Ixo-vec is designed as a single injection in a physician's office that gets the eye to produce steady levels of aflibercept on its own, which the companies say could cut the burden of ongoing shots ^[1].

The therapy is in the ARTEMIS Phase 3 trial, which has completed screening ^[1]. U.S. regulators have granted it Fast Track and Regenerative Medicine Advanced Therapy designations; European regulators granted PRIME status, and the UK's medicines agency issued an Innovation Passport ^[1]. None of that is approval, and no filing or approval date has been announced.

Adverum was running short on money. Lilly extended a promissory note of up to $65 million, drawable in four installments and secured by all of Adverum's assets, including its intellectual property, to keep the Ixo-vec trials going before closing ^[1]. Without that loan, Adverum's remaining cash was expected to cover only October 2025 operations and wind-down activities ^[1]. Adverum's board approved the deal unanimously after reviewing other buyers, partners and financing options ^[1].

The tender offer expired one minute after 11:59 p.m. Eastern on December 8, 2025, with 16,493,335 shares tendered — about 64% of Adverum's outstanding shares — satisfying all conditions ^[2].

Why it matters for patients

If you take or are considering a Lilly medicine such as tirzepatide, this deal does not change anything about your prescription, your pharmacy or your coverage. It is a corporate transaction, and Ixo-vec is an investigational product that is not approved or available outside of clinical trials ^[1][2].

What it does show is where Lilly is aiming next. The company describes the acquisition as a way to "expand gene therapy's potential to alleviate the burden of age-related conditions, including vision loss" ^[2], and it markets itself as a company focused on diabetes care, obesity and other chronic conditions ^[1]. Lilly's group vice president for molecule discovery, Andrew Adams, said Ixo-vec "has the potential to transform wAMD treatment from a paradigm of chronic care with repeated intravitreal injections to a convenient one-time therapy" ^[1].

One caution: wet AMD is a distinct condition from diabetes-related eye disease, and the announcements do not describe any use of Ixo-vec in diabetic eye conditions or any connection to Lilly's metabolic medicines.

What happens next

The merger closed on December 9, 2025, and Adverum's employees join Lilly ^[2]. The next milestone that matters is the ARTEMIS Phase 3 readout and any regulatory filing. Neither company has announced dates for those steps, and the contingent payments give a seven-year window for U.S. approval and a ten-year window for the sales target ^[1].